[The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses].

Abstract

The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.

• Authors: O A Mashkov, L I Mazur, A V Popov, B A Sorokin, Iu S Prokhorov
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 63 Issue 10 Pg. 138-41 ( 1991) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Pervyĭ klinicheskiĭ opyt primeneniia antiproteaznogo gemosorbenta "Ovosorb" v kompleksnom lechenii nekotorykh dermatozov.
• PMID: 1805413 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Acrylic Resins
• Protease Inhibitors
• Ovomucin
• polyacrylamide

Topics

• Acrylic Resins (therapeutic use)
• Adult
• Chronic Disease
• Combined Modality Therapy
• Female
• Hemoperfusion (methods)
• Humans
• Male
• Middle Aged
• Ovomucin (therapeutic use)
• Protease Inhibitors (therapeutic use)
• Skin Diseases (therapy)